Advances in the management of malignant mesothelioma

Current Oncology Reports

Volumn 5, Issue 4, 2003, Pages 334-341

  Khalil, Mazen Y ^a   Mapa, Marissa ^a   Shin, Hyung Ju C ^a   Shin, Dong M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GANCICLOVIR; GEFITINIB; GEMCITABINE; HUMAN SERUM ALBUMIN; IFOSFAMIDE; IMATINIB; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEMETREXED; RALTITREXED; RANPIRNASE; SEMAXANIB; THYMIDINE KINASE; TRIMETREXATE; UNINDEXED DRUG;

ALOPECIA; ANEMIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTHERMIC THERAPY; LEUKOPENIA; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PERICARDIUM; PERITONEAL CAVITY; PERITONEUM MESOTHELIOMA; PLEURA CAVITY; PLEURA MESOTHELIOMA; REVIEW; SEROSA; STANDARDIZATION; STOMATITIS; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM; CANCER STAGING; CONTROLLED CLINICAL TRIAL; FEMALE; GENE THERAPY; IMMUNOTHERAPY; LUNG TUMOR; MALE; MEDIASTINUM TUMOR; MESOTHELIOMA; METHODOLOGY; MORTALITY; PATHOLOGY; PLEURA TUMOR; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL; THORAX SURGERY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 0037658600     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0076-9     Document Type: Review

References (70)

1. Testa JR, Pass HI, Carbone M: Molecular biology of mesothelioma. In Cancer: Principles and Practice of Ooncology. Edited by Devita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2001:1937-1943.
2. Pass HI, Temeck, Kranada K, et al.: Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998, 115:310-317.
3. Sugarbaker DJ, Flores R, Jacklitsch M, et al.: Resection margins, extrapleural modal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-65.
4. Antman K, Shemin R, Ryan L, et al.: Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Bringham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988, 6:147-153.
5. Gordon W, Antman K, Breenberger J, et al.: Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982, 8:19-25.
6. Boutin C, Rey F, Viallat JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995, 108:754-758.
7. Rom WN, Travis WD, Bordy AR: Cellular and molecular basis of the asbestos-related disease. Am Rev Resp Dis 1991, 143:408-422.
8. Henderson DW, Shilkin KB, Whitaker D: Reactive mesothelial hyperplasia vs. mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Path 1998, 110:397-404.
9. Tiainen M, Tammilehto L, Mattson K, Knuutila S: Non-random chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 1998, 33:251-274.
10. Bell DW, Jhanwar SC, Testa JR: High resolution deletion mapping of putative tumor suppressor loci in chromosome 6q in malignant mesothelioma [abstract]. Proc Ann Meet Am Assoc Cancer Res 1996, 37:A4041.
11. Kratzke RA, Otterson GA, Lincoln CE, et al.: Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995, 87:1870-1875.
12. Xio S, Li D, Vijg J, Sugarbaker DJ, et al.: Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995, 11:511-515.
13. Hagemeijer A, Versenel MA, Van Drunen E, et al.: Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990, 47:1-28.
14. Chen Z, Wang DD, Peier A, et al.: FISH in the evaluation of pleural and ascitic fluids. Cancer Genet Cytogenet 1995 84:116-119.
15. Shin HJC, Shin DM, Tarco E, Sneige N: Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer (Cancer Cytopathol) 2003, in press.
16. Nowak AK, Lake RA, Kindler HL, et al.: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002, 29:82-96.
17. Strizzi L, Catalano G, Vinnale S, et al.: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathology 2001, 193:468-475.
18. Procopio A, Strizzi L, Vinale P, et al.: Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 2000, 29:173-179.
19. Carbone M, Fisher S, Powers A, et al.: New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol 1999, 180:167-172.
20. Hirvonen A, Mattson K, Karjalainen A, et al.: SV40-like sequences were not detected in Finnish mesotheliomas not exposed to SV40-contaminated polio vaccines. Mol Carcinogen 1999, 26:93-99.
21. Hubner R, Marck EV. Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura (Belgium). Cancer Causes Control 2002, 13:121-129.
22. Strizzi L, Vinale A, Catalano R: Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001, 18:1093-1098.
23. Cacciotti P, Strizzi L, Vinnale G, et al.: The presence of Simian-Virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Mol Biol 2002, 26:189-193.
24. Xie, YC, Hwang C, Overwijk W, et al.: Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst 1999, 91:169-175.
25. Sterman DH, Treat J, Litzky LA, et al.: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9:1083-1092.
26. Lanuti M, Gao GP, Force SD, et al.: Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 1999, 10:463-475.
27. Gordon GJ, Appasani K, Parcells J, et al.: Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002, 23:1017-1024.
28. Bandala E, Espinosa M, Maldonaldo V, et al.: Inhibitor of apoptosis (IAP-1) expression and apoptosis in non-small-cell lung cancer exposed to gemicitabine. Biochem Pharmacol 2001, 62:13-19.
29. Strizzi L, Muraro, R, Vianale G, et al.: Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol 2002, 197:218-223.
30. Fong TAT, Shawver LK, Sun L, et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk/KDR) that inhibits tyrosine kinase catalyst, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106.
31. Kindler HL, Vogelzang NJ, Chein K, et al.: SU5416 in malignant mesothelioma: University of Chicago phase II consortium study [abstract]. Proc ASCO 2001, 20:431a.
32. Buchdunger E, Cioffi CL, Law N, et al.: Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
33. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053-2063.
34. Ryan CW, Herndon J, Vogelzang NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 1998, 113(Suppl):66S-73S.
35. Taub RN, Antman KH: Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc 1997, 9:361-366.
36. Baas P: Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 2002, 29:62-69.
37. Solheim OP, Saeter G, Finnanger AM, et al.: High dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992, 65:956-960.
38. Brodin O, Knuutila A, Halme H, et al.: Combined treatment of malignant mesothelioma of the pleura with high dose methotrexate and interferon alpha and gamma. [abstract 53]. Presented at the Ninth World Conference on Lung Cancer. Tokyo, Japan. September 11-15, 2000.
39. Carmine P, Antonella M, Monica G, et al.: Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2001, 24:143-147.
40. Scheulen M, Gatzemeier U, Pawel J, et al.: Phase II study to assess the efficacy and tolerability of methotrexate-albumin (MTX-HAS) in first line chemotherapy of patients with advanced malignant mesothelioma (a study with the participation of CESAR-EWIV) [abstract]. Proc ASCO 2002, 21:20b. http://www.asco.org/
41. Vogelzang NJ, Weissman LB, Herndorn JE IJ, et al.: Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study. J Clin Oncol 1994, 12:1436-1442.
42. Kindler H, Belani CR Herndon JE II, et al.: Edatrexate (10-ethyl-deaza-aminopterin) (NSC: 626715) with or without leucovorin recue for malignant mesothelioma: sequential phase II trials by the CALGB. Cancer 1999, 86:1985-1991.
43. Kindler HL, Millard F, Herndon JE II: Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31:311-317.
44. Van Meerbeeck, Baas P, Debruyne C, et al.: A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999, 85:2577-2582.
45. Bischoff HG, Manegold C, Knopp M, et al.: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma [abstract]. Proc ASCO 1998, 17:464. http://www.asco.org/
46. Davidson JA, Robinson BWS: Gemcitabine activity on murine and human malignant mesothelioma cells lines show additve activity in combination with cisplatin [abstract]. Aust NZ J Med 1997, 27:213.
47. Aversa SML, Favaretto AG: Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV. Clin Lung Cancer 1999, 1:73-75.
48. van Haarst JW, Burgers JA, Manegold CH, et al.: Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM) [abstract]. Lung Cancer 2000, 29(suppl):18.
49. Nowak A, Byrne M, Williamson R, et al.: Multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma (MM) [abstract]. Ann Oncol 2000, 1(suppl):109.
50. Byrne MJ, Davidson JA, Musk AW, et al.: Cisplatin and gemcitabine for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25-30.
51. Pinto C, Marino, A, Manzini V, et al.: Phase II trial of sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in untreated malignant pleural mesothelioma (MPM) [abstract]. Proc ASCO 2002, 21:1644. http//www.asco.org/
52. Schuette W: A phase II trial of gemcitabin/oxaliplatin combination chemotherapy in stage II-IV malignant pleural mesothelioma [abstract]. Proc ASCO 2002, 21:334a. http//www.asco.org/
53. Vogelzang N, Taub R, Shin D, et al.: Phase III randomized trial of onconase (ONC) vs doxorubicin (DOX) in patients with unresectable malignant mesothelioma (UMM): analysis of survival [abstract 2274]. Proc ASCO 2000, 19:577a. http//www.asco.org/
54. Fizazi K, Ducreux M, Ruffie P et al.: Phase 1, dose finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in pats with advanced cancer. J Clin Oncol 2000, 18:2293-3000.
55. Fizazi K, Caliandro R, Soulie P, et al.: Combination raltitrexed (Tomudex)-oxaliplatin: a step forward in the struggle against mesothelioma: the Institut Gustav Roussy experience with chemotherapy and chemo-immumotherapy in mesothelioma. Eur J Cancer 2000, 36:1514-1521.
56. Steele JPC, Shamash J, Evans MT, et al.: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000, 18:3912-3918.
57. Bakhshandeh A, Bruns I, Eeberhardt K, et al.: Results of a phase II study for adult patients with malignant pleural mesothelioma: ifosfamid (IFO), carboplatin (CBDCA) and etoposid (VP-16) combined with whole body hyperthermia (WBH) [abstract]. Proc ASCO 2002, 21:1633. http//www.asco.org/
58. Thodtmann R, Depenbrock H, Dumez, et al.: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999, 17:3009-3016.
59. Hughes A, Calvert P, Azzabi A, et al.: Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant mesothelioma. J Clin Oncol 2002, 20:3533-2544
60. Shin DM, Scagliotti G, Kindler H, et al.: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function [abstract]. Proc ASCO 2002, 21:294a. http//www.asco.org/
61. Vogelzang N, Rusthoven J, Paoletti P, et al.: Phase III single-blinded study of pemetrexed plus cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma [abstract]. Proc ASCO 2002, 21:2a. http//www.asco.org/
62. Baldini EH, Recht A, Strauss GM, et al.: Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997, 63:334-338.
63. Rusch V, Figlin R, Godwin D, et al.: Intrapleural cisplatin and cytarabine in the management of malignant pleural effusion: a Lung Cancer Study Group Trial. J Clin Oncol 1991, 9:313-319.
64. Rusch V, Saltz L, Venkatraman E, et al.: A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant mesothelioma. J Clin Oncol 1994, 12:1156-1163.
65. Juturi JV, Adelstein DJ, Rice TW, et al.: Intracavitary paclitaxel in the multimodality management of malignant pleural mesothelioma [abstract]. Proc ASCO 2001, 20:366a. http://www.asco.org/
66. Ratto GB, Civalleri D, Esposito M, et al.: Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999, 117:759-756.
67. Perez-Soler R, Francis K, Al-Baker S, et al.: Preparation and characterization of a liposomal preparation containing a lipophilic cisplatin derivative for clinical use. J Microencapsul 1994, 11:41-54.
68. Perez-Soler R, Shin DM, Siddik ZH, et al.: Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusion. Clin Cancer Res 1997, 3:373-379.
69. Perez-Soler R, Walsh GL, Swisher SG, et al.: Phase II study of a liposome-entrapped cisplatin analong (L-NDDP) administered intrapleurally in patients with MPM [abstract]. Proc ASCO 1999, 18. http://www.asco.org/
70. Shin DM: Pathologic response with liposomal-entrapped cisplatin analong (L-NDDP) administered in patients with malignant pleural mesothelioma: phase II clinical study [abstract]. Presented at the Ninth World Conference on Lung Cancer. Tokyo, Japan. September 11-15, 2000.